Search

Halozyme Therapeutics Inc

Fechado

SetorSaúde

78.68 0.7

Visão Geral

Variação de preço das ações

24h

Atual

Mín

76.91

Máximo

78.58

Indicadores-chave

By Trading Economics

Rendimento

292M

150M

Vendas

-75M

377M

P/E

Médio do Setor

27.337

62.58

EPS

1.221

Margem de lucro

39.832

Funcionários

423

EBITDA

-62M

220M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+5.07% upside

Dividendos

By Acuity

Próximos Ganhos

4 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.5B

9.1B

Abertura anterior

77.98

Fecho anterior

78.68

Sentimento de Notícias

By Acuity

27%

73%

62 / 340 Ranking em Healthcare

Halozyme Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

21 de jul. de 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

21 de jul. de 2026, 23:51 UTC

News
Social Media

Pegasystems shares declined in after-market trading following second-quarter results that missed analyst expectations for earnings and revenue, amid concerns over future ACV growth.

21 de jul. de 2026, 23:46 UTC

News

Adobe Inc. shares are declining in after-market trading following Morgan Stanley's downgrade to "underweight" and a reduced price target of $240.

21 de jul. de 2026, 23:41 UTC

News

Raytheon Technologies secures a $49.7 million Navy contract for weapon system repairs, with shares trading higher in after-market hours.

21 de jul. de 2026, 23:41 UTC

Social Media
News

Capital One Financial reported adjusted EPS of $5.81 and revenue of $15.85 billion, exceeding expectations, as shares rose in after-market trading.

21 de jul. de 2026, 23:41 UTC

Macro News
ETF Constituents
News

Vanguard Information Technology ETF is little changed after market hours, despite broader market gains and negative contributions from Apple, Microsoft, and Nvidia.

21 de jul. de 2026, 23:36 UTC

News
ETF Constituents

The Vanguard Growth ETF is trading roughly flat in after-market hours, reflecting minor fluctuations among its holdings, including declines from Apple, Microsoft, and Nvidia.

21 de jul. de 2026, 23:36 UTC

Social Media
News

Micron Technology rose in after-market hours, supported by a semiconductor rally and a Bank of America upgrade to "buy" on strong AI demand.

21 de jul. de 2026, 23:36 UTC

News

MongoDB shares traded higher after director Dwight Merriman sold 16,000 shares for $5.2 million under a pre-scheduled plan, retaining $496.55 million in holdings.

21 de jul. de 2026, 23:32 UTC

News

United Community Banks Inc. shares rise in after-market trading after an upgrade to Buy, bolstered by Q2 2026 net interest income of $270.7 million.

21 de jul. de 2026, 23:26 UTC

Correlated Moves
News

JPMorgan Chase & Co shares showed little change in after-market hours amid broader market movements. CEO Jamie Dimon raised concerns over geopolitical tensions and inflation.

21 de jul. de 2026, 23:26 UTC

Social Media
Correlated Moves
News

Coinbase Global shares rose in after-market trading amid reports of a regulatory agreement that may benefit digital assets, with Bitcoin approaching $67,000.

21 de jul. de 2026, 23:26 UTC

News

Lucid Group Inc. faces a class action lawsuit over alleged supplier quality issues, contributing to a decline in after-market trading. Shares earlier stabilized after a session low.

21 de jul. de 2026, 23:26 UTC

News

Intuit Inc. shares are lower in after-market trading following a class action lawsuit alleging misleading statements about TurboTax revenue growth and competitive advantages.

21 de jul. de 2026, 23:16 UTC

News

Sprinklr Inc reported first-quarter revenues of $219.5 million, exceeding expectations, but shares are lower in after-market hours amid sector concerns and mixed AI sentiments.

21 de jul. de 2026, 23:16 UTC

News

Nasdaq shares rise in after-market hours following the dismissal of all claims in the Miami International litigation, positively impacting investor sentiment.

21 de jul. de 2026, 23:16 UTC

News

Iridium Communications Inc. shares are higher in after-hours trading, reflecting positive market sentiment amid significant gains in technology and semiconductor stocks in Asia.

21 de jul. de 2026, 23:16 UTC

News

Intel faces valuation scrutiny as modest growth expectations contrast with sector leaders benefiting from AI demand. Shares were roughly flat in after-market hours.

21 de jul. de 2026, 23:11 UTC

News

Toast Inc shares are trading higher in after-market hours following the announcement of its second quarter 2026 financial results release on August 4.

21 de jul. de 2026, 23:11 UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

21 de jul. de 2026, 23:06 UTC

News

General Motors plans a new generation of gasoline-powered Cadillac models, shifting from an all-electric strategy. Shares are higher in after-market trading.

21 de jul. de 2026, 23:02 UTC

News

Park Aerospace shares lower in after-market hours following the unexpected death of Vice President Daniel McNamara, impacting investor sentiment and contributing to the decline.

21 de jul. de 2026, 23:02 UTC

Event
News

Weatherford International shares advanced in after-market trading following second-quarter results, with revenues of $1.11 billion exceeding expectations despite a decline.

21 de jul. de 2026, 23:02 UTC

News

Jefferies raised its price target on Genuine Parts Co to $130.00, contributing to after-market gains following a dip earlier in the session.

21 de jul. de 2026, 23:02 UTC

Event
News
Social Media

AAR Corp shares are lower in after-market trading following mixed fourth-quarter results and cautious guidance, despite exceeding sales and EPS expectations.

21 de jul. de 2026, 23:02 UTC

News

ServiceNow Inc. shares declined in after-market hours amid concerns about generative AI's impact on the enterprise software sector, according to Morgan Stanley.

21 de jul. de 2026, 23:01 UTC

News
Social Media

Citigroup Inc declared a quarterly dividend of $0.67 per share, though shares are trading lower after-market amid ongoing market weakness.

21 de jul. de 2026, 23:01 UTC

News

Norfolk Southern announced a quarterly dividend of $1.35 per share, contributing to shares trading higher in after-market hours following three lower sessions.

21 de jul. de 2026, 23:01 UTC

News

DigitalOcean shares rise in after-market hours after Baird analyst initiates coverage with an Outperform rating. The stock closed at $119.09 in the prior session.

21 de jul. de 2026, 23:01 UTC

News
Social Media

Chubb Ltd reported second-quarter net income of $2.85 billion, down from $2.97 billion a year earlier, contributing to lower after-market trading.

Comparação entre Pares

Variação de preço

Halozyme Therapeutics Inc Previsão

Preço-alvo

By TipRanks

5.07% parte superior

Previsão para 12 meses

Média 81 USD  5.07%

Máximo 96 USD

Mínimo 57 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

3

Comprar

2

Manter

1

Vender

Sentimento

By Acuity

62 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
help-icon Live chat